Ewing Sarcoma (ES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Ewing sarcoma (ES), a peripheral primitive neuroectodermal tumor, is a malignancy originating from a specific cell type in either bone or soft tissue. This tumor condition is characterized by chromosomal rearrangements involving the long arms (q) of chromosomes 11 and 22 (11q24-22q12), resulting in the abnormal fusion of two genes, typically EWS and FLI. The standard approach to treating ES, whether it has metastasized or not, involves a multidisciplinary approach that includes chemotherapy and local therapies such as surgery and radiotherapy (RT). Complications associated with Ewing sarcoma may include metastasis, local recurrence, secondary cancers, pathological fractures, and morbidities associated with surgery, radiation, and chemotherapy. Ewing sarcoma primarily affects adolescents and young adults, with a median age of onset at 15 years. It accounts for less than 5% of all soft tissue sarcomas. The highest incidence occurs between the ages of 10 and 15, with approximately 30% of cases diagnosed in children under 10 and another 30% in adults over 20. There is a notable male predominance, with a male-to-female ratio of 3 to 1.
• The annual incidence of Ewing sarcoma is approximately 2.93 cases per 100,000 children.

Thelansis’s “Ewing Sarcoma (ES) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ewing Sarcoma (ES) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Ewing Sarcoma (ES) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Ewing Sarcoma (ES) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Ewing Sarcoma (ES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Ewing Sarcoma (ES), Ewing Sarcoma (ES) market outlook, Ewing Sarcoma (ES) competitive landscape, Ewing Sarcoma (ES) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)